Home›Trial›NCT04232553
🔬NCT04232553Phase 3ACTIVE NOT RECRUITING

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Study Summary

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Conditions
Crohn's Disease
Interventions / Drugs
Mirikizumab
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment996 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.866766+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.